This interview discusses candidate selection, toxicity monitoring, access considerations, and evolving clinical applications of menin inhibitors in acute myeloid leukemia (AML).
Bernard Marini, PharmD, BCOP, FHOPA
Advertisement
Articles by Bernard Marini, PharmD, BCOP, FHOPA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients
2
Pharmacists Are Critical to SGLT2, GLP-1 Use in CKD
3
FDA Expands Lutetium Lu 177 Vipivotide Tetraxetan to mHSPC, Nearly Doubling Eligible Population
4
Inside Phoebe Putney’s Medication Management Clinic: How One Rural Health System Saved $1 Million and Cut Readmissions
5